Business UpdateJul 7, 2026, 07:31 AM
BriaCell Engages CRA, Kaleio for Bria-IMT Commercial Strategy
AI Summary
BriaCell Therapeutics Corp. announced it has engaged Charles River Associates (CRA) and Kaleio, Inc. to support commercial strategy, market access evaluation, and brand planning for its drug candidate, Bria-IMT. CRA will evaluate epidemiology, pricing, prescriber dynamics, and market access potential in metastatic breast cancer, while Kaleio will focus on brand strategies. Bria-IMT is currently undergoing a pivotal Phase 3 study, and these engagements are a proactive step towards potential future commercialization.
Key Highlights
- BriaCell engaged Charles River Associates (CRA) for Bria-IMT market evaluation.
- CRA will assess epidemiology, pricing, prescriber dynamics, and market access for Bria-IMT.
- Kaleio, Inc. was engaged to support brand strategies and commercial-readiness solutions.
- Bria-IMT is currently in an ongoing pivotal Phase 3 study for metastatic breast cancer.
- Engagements represent a prudent commercial-readiness step for potential future commercialization.
Price Impact
More from BCTX